Geneos Wealth Management Inc. Buys 248 Shares of IQVIA Holdings Inc. $IQV

Geneos Wealth Management Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,472 shares of the medical research company’s stock after purchasing an additional 248 shares during the quarter. Geneos Wealth Management Inc.’s holdings in IQVIA were worth $1,494,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of IQV. Pacer Advisors Inc. raised its position in shares of IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares in the last quarter. Hawk Ridge Capital Management LP acquired a new position in shares of IQVIA in the first quarter valued at about $77,096,000. Nuveen LLC acquired a new position in shares of IQVIA in the first quarter valued at about $76,328,000. Finally, GAMMA Investing LLC grew its stake in shares of IQVIA by 27,448.4% in the first quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company’s stock valued at $68,286,000 after acquiring an additional 385,925 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

IQV has been the topic of several research reports. Evercore ISI upped their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Citigroup restated a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group increased their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Finally, Mizuho increased their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $229.64.

IQVIA Trading Down 1.8%

Shares of IQVIA stock opened at $187.34 on Friday. The company has a market capitalization of $31.85 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 2.09 and a beta of 1.32. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $248.03. The firm’s 50-day moving average price is $182.40 and its two-hundred day moving average price is $167.42.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.